Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04838444 · ClinicalTrials.gov registry record · Phase 3
Antibody Persistence And Long Term Safety Of A Chikungunya Virus Vaccine (VLA1553)
A Phase 3 study of Chikungunya Virus Infection, sponsored by Valneva Austria.
- Active
- Registry status
- Phase 3
- Development phase
- 363
- Enrollment target
- 10
- Study locations
NCT04838444: Active Phase 3 study of Chikungunya Virus Infection, sponsored by Valneva Austria.
NCT04838444 is a Phase 3 study of Chikungunya Virus Infection that is active but no longer recruiting, run by Valneva Austria. The registered enrollment target is 363 participants, roughly in line with the 367-participant average among 4 other Chikungunya Virus Infection trials with a reported enrollment target. The trial reports 10 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04838444, a Phase 3 study of Chikungunya Virus Infection, is active but no longer recruiting, sponsored by Valneva Austria.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 363 participants
- Enrollment target
- 10
- Study locations
Study Summary
In this open-label Phase 3b, single arm trial, persistence of antibodies and long term safety will be evaluated in up to 375 participants rolled over from trial VLA1553-301 (NCT number: NCT04546724).
Primary Outcome
Data for Visit 1 - Day 1 are collected from Trial VLA1553-301
Conditions Studied
Interventions
- BIOLOGICAL VLA1553
Study Locations (10)
Nebraska
- Velocity Clinical Research - Grand Island
- Velocity Clinical Research - Omaha
Arizona
- Accelerated Enrollment Solutions (AES) - Phoenix
Florida
- Velocity Clinical Research - Hallandale
Illinois
- Accelerated Enrollment Solutions (AES) - Chicago
Kentucky
- Alliance for Multispecialty Research (AMR) - Lexington
Tennessee
- Alliance for Multispecialty Research (AMR) - Knoxville
Texas
- Velocity Clinical Research - Austin
Utah
- Velocity Clinical Research - West Jordan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 363 participants |
| Start Date | 2021-04-02 |
| Est. Completion | 2031-05 |
| Phase | Phase 3 |
What the registry record for NCT04838444 still lists
NCT04838444 is an interventional study that assigns participants to a tested intervention. The registered 363 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 367-participant average among 4 other Chikungunya Virus Infection trials with a reported enrollment target.
The record links to 1 condition, with Chikungunya Virus Infection appearing as the primary indexed condition, and to 1 intervention - of which VLA1553 is the first listed.
NCT04838444 lists 10 locations in 9 states (Nebraska, Arizona, Florida).
Frequently Asked Questions
What is clinical trial NCT04838444 about?
NCT04838444 is a clinical study titled "Antibody Persistence And Long Term Safety Of A Chikungunya Virus Vaccine (VLA1553)". In this open-label Phase 3b, single arm trial, persistence of antibodies and long term safety will be evaluated in up to 375 participants rolled over from trial VLA1553-301 (NCT number: NCT04546724).
What is the current status of trial NCT04838444?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 363 participants. The study started on 2021-04-02. Estimated completion is 2031-05.
What conditions does trial NCT04838444 study?
This clinical trial studies the following conditions: Chikungunya Virus Infection.
What interventions are being tested in trial NCT04838444?
The interventions under investigation include: VLA1553 (BIOLOGICAL).
Who is sponsoring clinical trial NCT04838444?
This trial is sponsored by Valneva Austria, which has 11 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04838444 being conducted?
This trial has 10 study locations across Arizona, Florida, Illinois, Kentucky, Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chikungunya Virus Infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Long-term Follow-up Study to Evaluate Safety and Immunogenicity of PXVX0317 Single or Booster Vaccination
ACTIVE NOT RECRUITING · Phase 3
-
Phase 1 Study of SAR440894 vs Placebo
COMPLETED · Phase 1
-
Trial of a Chikungunya Vaccine, PXVX0317 CHIKV-VLP, in Healthy Adults
COMPLETED · Phase 2
-
Phase I Trial of Measles Vectored Chikungungya Vaccine
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06472245 · 363 participants · Phase 3
Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor
- NCT04510597 · 364 participants · Phase 3
Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial
- NCT05098132 · 364 participants · Phase 1
Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers
- NCT05330221 · 364 participants · NA
Project 2: ACHIEVE- HF
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI